We are very pleased to announce the start of our collaboration with Dr. Julian Hellmann-Regen, Head of the Clinical Neurobiology Laboratory at the Charité Universitätsmedizin, Berlin. Dr. Hellmann and his team will further investigate the molecular mode of action of our lead candidate AC102.
